VisionX, a company dedicated to the research and development of a full set of innovative solutions for medical devices in the field of ophthalmic ophthalmology, has recently completed its Series A financing round, and has secured Series A+ round, with an overall financing amount of more than 100 million yuan.
The latest round was led by Sequoia Capital, and joined by Sherpa Venture Capital, Fosun Capital, Green Pine Capital Partners, bioVentue, Hengqin Financial Investment, and others.
The proceeds will be used to accelerate the research and development, clinical and registration process of a number of optometry medical device products of VisionX.
As a distinctive medical device manufacturer in the field of ophthalmology, VisionX is mainly involved in the prevention and control of youth myopia, adult vision correction and treatment of ocular surface diseases, contact lens care products and ophthalmology examination equipment.
The company is also in the process of launching two new business segments, including a complete line of contact lens care products and optometry-related examination equipment.